Targeted Molecular Therapy for Neuroblastoma: The ARF/MDM2/p53 Axis
نویسندگان
چکیده
منابع مشابه
Advances in ALK Targeted Therapy for Neuroblastoma
Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and pr...
متن کاملTargeted radiotherapy for neuroblastoma.
Background Biologically targeted radiotherapy is an established treatment for thyrotoxicosis and thyroid cancer. The principle is to take advantage of the ability of the thyroid and, to a lesser degree, diVerentiated thyroid carcinoma to concentrate and retain iodide. In this situation the radionuclide (I) in ionic form is a natural substrate for targeting thyroid tissue, thus acting both as th...
متن کاملMolecular Markers in Neuroblastoma
Neuroblastoma, one of the common malignant childhood tumors, arises from neuroblast cells derived from theneural crest and destined for the adrenal medulla and the sympathetic nervous system and shows remarkable biologicalheterogeneity, resulting in favorable or unfavorable outcomes. Some tumors make rapid progress with a fataloutcome. In other instances, the tumors regress spontaneously in inf...
متن کاملApatinib for molecular targeted therapy in tumor
As tumor angiogenesis is one of the hallmarks of cancer, the inhibition of vascular endothelial growth factor signaling has become an attractive anticancer approach. Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor-2, has demonstrated encouraging anticancer activity across a broad range of malignancies, including gastric cancer, non-small-cell lung cancer, bre...
متن کاملMolecular targeted therapy for advanced gastric cancer
Although medical treatment has been shown to improve quality of life and prolong survival, no significant progress has been made in the treatment of advanced gastric cancer (AGC) within the last two decades. Thus, the optimum standard first-line chemotherapy regimen for AGC remains debatable, and most responses to chemotherapy are partial and of short duration; the median survival is approximat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2009
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/djp376